Original ArticleAntidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs
Section snippets
METHODS
The MarketScan Medicare Supplemental and Coordination of Benefits database was used for this study. The time period of claims assessed was January 2001 to December 2006. The database contains individual-level, deidentified insurance claims from retirees in the United States with primary or Medicare supplemental coverage through privately insured health plans. The Medicare Supplemental Database includes both the employer-paid and Medicare-paid components of care.
Adults who had at least one claim
RESULTS
The MarketScan Medicare database for 2001–2006 comprised 3,407,362 individuals; of these, 558,354 (16%) had an antidepressant prescription claim between July 1, 2001, and December 31, 2005, and 116,747 (3.4%) had an antidepressant claim and a depression diagnosis. A subset of 39,512 patients met the continuous enrollment criteria and had a clean period of 6 months with no antidepressant utilization prior their index date. Of these 39,512 patients, 18% filled a tricyclic or tetracyclic
CONCLUSION
Although antidepressant medications have been demonstrated to be effective in treatment of geriatric depression, this study highlights the complexity of antidepressant prescribing in this population. In contrast to older adults who do not use antidepressants, older adults who use antidepressants have more psychiatric and physical comorbid illness, and use a greater variety of medications. Physical comorbidities put patients at increased risk of depression, and depression may worsen the course
References (20)
- et al.
Practical considerations on the use of the Charlson comorbidity index with administrative data bases
J Clin Epidemiol
(1996) - et al.
A chronic disease score from automated pharmacy data
J Clin Epidemiol
(1992) - et al.
What are older peoples' experiences of taking antidepressants?
J Affect Disord
(2002) - et al.
Depressive episodes and dysphoria resulting from conjugal bereavement in a prospective community sample
Am J Psychiatry
(1990) - et al.
Depression through the first year after the death of a spouse
Am J Psychiatry
(1991) - et al.
A longitudinal study of risk factors for depressive symptomatology in elderly widowed and married women
Am J Epidemiol
(1991) - et al.
A prospective study of widowhood and changes in symptoms of depression in a community sample of the elderly
Psychol Med
(1994) - et al.
The development of depressive symptoms in elderly following onset of severe physical illness
J Fam Pract
(1988) - et al.
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Neurology
(1992) - et al.
Increases in depressive symptomatology in the rural elderly: results from a cross-sectional and longitudinal study
J Abnorm Psychol
(1992)
Cited by (61)
When to stop medication in unipolar depression: A systematic review and a meta-analysis of randomized controlled trials
2023, Journal of Affective DisordersSocial and economic factors associated with antidepressant use: Results of a national survey in primary care
2022, Journal of Affective Disorders ReportsComparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study
2022, Journal of Affective DisordersCitation Excerpt :Furthermore, depression in this age group is often concurrent with medical illnesses such as hypertension, diabetes mellitus, or dementia (Blazer, 2003; Greenblatt et al., 1998) and drugs for those comorbidities may have potential interactions with antidepressants (Teply et al., 2016). Finally, side effects of antidepressants, such as nausea, constipation, dizziness, headache, and sleep disturbance, impact antidepressant adherence among geriatric populations, by increasing antidepressant switching rate and discontinuation rate (Mark et al., 2011). Therefore, studying the overall effectiveness of antidepressant medications in the elderly people is a necessity.
Association of Antidepressants With Recurrent, Injurious and Unexplained Falls is Not Explained by Reduced Gait Speed
2020, American Journal of Geriatric PsychiatryBayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression
2019, Contemporary Clinical Trials CommunicationsThe beneficial effects of Qigong on elderly depression
2019, International Review of Neurobiology
The authors thank Laurie Costa for excellent programming support.
This work was supported by Sanofi Aventis (to Thomson Reuters).
The study was presented as a poster in 2009 at the International Society for Pharmacoepidiology, the International Society for Pharmacoeconomics and Outcomes Research, the American Academy of Geriatric Psychiatry, and the American Society of Consultant Pharmacists.
Disclosure of Interests: Dr. Mark, Dr. Cao, and Mr. Johnston are employees of Thomson Reuters and as such have worked on projects that were funded through contracts to Thomson Reuters from major pharmaceutical companies including Alkermes, Boehringer Ingelheim, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Merck, Pfizer, Inc., Novartis Pharmaceuticals Corp, Pharmacia, Roche, Sanofi-Aventis, and Schering Corporation; Dr. Vijay Joish was an employee of sanofi-aventis, USA, sponsor of this study, at the time the study was conducted; Dr. Hay has received research support for this study from sanofi-aventis, USA, and is also on a sanofi-aventis advisory board; David V Sheehan, MD, MBA, has received grant funding support, or been affiliated or received honoraria and travel expenses related to lectures/presentations or consultant activities from the following organizations: Abbott Laboratories, Ad Hoc Committee, Treatment Drug & Assessment Research Review, Alexa, Alza Pharmaceuticals, Palo Alto, CA, American Medical Association, American Psychiatric Association Task Force on Benzodiazepine Dependency, American Psychiatric Association Task Force on Treatments of Psychiatric Disorders, American Psychiatric Association Working Group to revise DSM-III Anxiety Disorders Section, Anclote Foundation, Anxiety Disorders Resource Center, Anxiety Drug Efficacy Case, U.S. Food & Drug Administration, Applied health Outcomes/XCENDA, AstraZeneca, Avera Pharmaceuticals, Boehringer Ingelheim, Boots Pharmaceuticals, Bristol-Myers Squibb, Burroughs Wellcome, Cephalon, Charter Hospitals, Ciba Geigy, Committee (RRC) of N.I.M.H. on Anxiety and Phobic Disorder Projects,1 Connecticut & Ohio Academies of Family Physicians, Cortex Pharmaceutical,1 Council on Anxiety Disorders, CPC Coliseum Medical Center, Cypress Bioscience, Dista Products Company, Division of Drugs & Technology, American Medical Association, EISAI, Eli Lilly, Excerpta Medica Asia, Faxmed, Inc, Forest Laboratories, Glaxo Pharmaceuticals, GlaxoSmithKline, Glaxo-Wellcome, Hospital Corporation of America, Humana, ICI, INC Research, International Clinical Research (ICR), International Society for CNS Drug Development (ISCDD),1 Janssen Pharmaceutica, Jazz Pharmaceuticals, Kali-Duphar, Labopharm, Layton Bioscience, Lilly Research Laboratories, Lundbeck, Denmark, Marion Merrill Dow, McNeil Pharmaceuticals, Mead Johnson, Medical Outcome Systems, MediciNova Merck Sharp & Dohme, National Anxiety Awareness Program, National Anxiety Foundation, National Depressive & Manic Depressive Association, National Institute of Drug Abuse, National Institute of Health (NIH), Novartis Pharmaceuticals Corp., Novo Nordisk, Organon,1,3 Orion Pharma, Parexel International Corporation, Parke-Davis, Pfizer, Pharmacia, Pharmacia & Upjohn, Philadelphia College of Pharmacy & Science, Pierre Fabre, France, Quintiles, Rhone Laboratories, Rhone-Poulenc Rorer Pharmaceuticals, Roche, Roerig, Sandoz Pharmaceuticals, Sanofi-Aventis, Sanofi-Synthelabo Recherche, Schering Corporation, Sepracor, Shire Laboratories, Inc., SmithKlineBeecham, Solvay Pharmaceuticals, Takeda Pharmaceuticals, Tampa General Hosp. University of South Florida Psychiatry Center, University of South Florida College of Medicine, TAP Pharmaceuticals, Targacept, TGH-University Psychiatry Center, Tikvah Therapeutics, Titan Pharmaceuticals, United Bioscience, The Upjohn Company, U.S. Congress-House of Representatives Committee, USF Friends of Research in Psychiatry, Board of Trustees, Warner Chilcott, World Health Organization, Worldwide Clinical Trials, Wyeth-Ayerst, ZARS, and Zeneca Pharmaceuticals.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.AJGPonline.org).